Want to see CH:PPGN full AI Analyst Report?
Top Page
PolyPeptide Group AG
(PPGN)
Select Model
Select Model
Rating:56Neutral
Price Target:
CHF45.00
▲(2.86% Upside)
Action:Reiterated
Date:07/04/26
The score is held back mainly by weak financial performance (continued net losses and volatile free cash flow) and unattractive earnings-based valuation (negative P/E). These are partly offset by strong technical momentum with price well above key moving averages, though overbought indicators add near-term risk.
Positive Factors
CDMO model & service breadth
PolyPeptide’s CDMO model provides diversified, fee-based revenue across development and commercial stages for peptide and oligonucleotide APIs. Lifecycle coverage (R&D to commercial supply) creates recurring commercial-volume potential and customer stickiness that supports durable revenue streams once drugs scale.
Negative Factors
Persistent net losses
Ongoing net losses erode retained earnings and limit the company’s ability to self-fund growth or cushion setbacks. Until sustained profitability is restored, reliance on external financing may increase, raising dilution or interest costs and constraining strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
CDMO model & service breadth
PolyPeptide’s CDMO model provides diversified, fee-based revenue across development and commercial stages for peptide and oligonucleotide APIs. Lifecycle coverage (R&D to commercial supply) creates recurring commercial-volume potential and customer stickiness that supports durable revenue streams once drugs scale.
Read all positive factors
PolyPeptide Group AG (PPGN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF1.45B
Dividend YieldN/A
Average Volume (3M)34.07K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue Growth13.85%
EPS Growth-7.03%
CountryCH
Employees1,440
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.64
Shares Outstanding33,125,000
10 Day Avg. Volume33,840
30 Day Avg. Volume34,067
Financial Highlights & Ratios
PEG Ratio-5.17
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF40.50Price Target Upside-7.43% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.78
Revenue Forecast (FY)CHF490.06M
PolyPeptide Group AG Business Overview & Revenue Model
Company Description
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic f...
How the Company Makes Money
PolyPeptide Group makes money primarily by providing fee-based CDMO services to pharmaceutical and biotech customers that outsource the development and manufacture of peptide (and, more recently, oligonucleotide) APIs. Its core revenue stream is c...
PolyPeptide Group AG Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
63
Positive
Cash Flow
51
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 391.87M | 338.69M | 320.37M | 280.98M | 282.13M |
| Gross Profit | 64.32M | 39.27M | 4.77M | 51.99M | 99.70M |
| EBITDA | 44.42M | 28.42M | -22.15M | 35.72M | 83.35M |
| Net Income | -21.31M | -19.56M | -51.44M | 7.77M | 47.26M |
Balance Sheet | |||||
| Total Assets | 825.31M | 756.58M | 689.09M | 575.78M | 595.04M |
| Cash, Cash Equivalents and Short-Term Investments | 74.53M | 68.28M | 95.71M | 37.53M | 136.30M |
| Total Debt | 130.46M | 94.12M | 113.66M | 21.22M | 18.00M |
| Total Liabilities | 484.98M | 399.33M | 307.86M | 154.10M | 173.87M |
| Stockholders Equity | 340.33M | 357.24M | 381.23M | 421.68M | 421.17M |
Cash Flow | |||||
| Free Cash Flow | -30.44M | 2.43M | -20.25M | -69.64M | -16.61M |
| Operating Cash Flow | 78.02M | 89.40M | 36.48M | 5.46M | 57.35M |
| Investing Cash Flow | -112.44M | -91.02M | -59.51M | -78.44M | -80.84M |
| Financing Cash Flow | 34.01M | -25.32M | 84.55M | -26.87M | 130.93M |
PolyPeptide Group AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | CHF3.42B | 19.68 | 15.68% | 0.57% | 2.57% | 4.31% | |
67 Neutral | CHF5.61B | 37.59 | 10.56% | 1.20% | 4.51% | 11.05% | |
66 Neutral | CHF38.31B | -365.06 | ― | 0.91% | -10.77% | -114.77% | |
66 Neutral | CHF41.27B | 53.21 | ― | 0.20% | 15.78% | 111.61% | |
62 Neutral | CHF28.93B | 38.23 | 10.09% | 1.26% | 0.80% | 28043.55% | |
56 Neutral | CHF1.45B | -73.48 | ― | ― | 13.85% | -7.03% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
CH:PPGN
PolyPeptide Group AG
43.95
22.80
107.80%
CH:LONN
Lonza Group Ltd
566.60
22.51
4.14%
CH:BANB
Bachem Holding AG
72.75
6.36
9.57%
CH:SFZN
Siegfried Holding AG
77.90
-8.85
-10.21%
CH:SDZ
Sandoz Group Ltd
69.18
19.27
38.60%
CH:GALD
Galderma Group AG
178.25
48.13
36.99%
PolyPeptide Group AG Corporate Events
Samsung Biologics Moves to Acquire Fast‑Growing Peptide CDMO PolyPeptide
Jul 20, 2026
PolyPeptide Group AG, a specialist in peptide‑based active pharmaceutical ingredients, reported strong operational momentum in the first half of 2026, underpinned by surging demand in metabolic therapeutics. The company’s growing expos...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.